Drug General Information (ID: DDIMXG8HPF)
  Drug Name Balsalazide Drug Info Flucytosine Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antiinflammatory Agents Antifungal Agents
  Structure

 Mechanism of Balsalazide-Flucytosine Interaction (Severity Level: Moderate)
     Decreased renal excretion due to nephrotoxicity Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Balsalazide Flucytosine
      Mechanism Nephrotoxicity Primarily eliminated by renal excretion
      Key Mechanism Factor 1
Factor Name Nephrotoxicity
Factor Description Drug-induced nephrotoxicity is a common and potentially serious complication of medication use. The kidneys are the primary organ for drug excretion, and when they are damaged can lead to decreased drug excretion.
      Mechanism Description
  • Decreased renal excretion of Flucytosine caused by Balsalazide mediated nephrotoxicity

Recommended Action
      Management Caution is advised if flucytosine is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides polypeptide, glycopeptide, and polymyxin antibiotics amphotericin B adefovir cidofovir tenofovir foscarnet cisplatin deferasirox gallium nitrate lithium mesalamine certain immunosuppressants intravenous bisphosphonates intravenous pentamidine high intravenous dosages of methotrexate high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).

References
1 Product Information. Ancobon (flucytosine). Roche Laboratories, Nutley, NJ.